The relation between the placebo response, observed treatment effect, and failure to meet primary endpoint: A systematic review of clinical trials of preventative pharmacological migraine treatments
Authors:
- 22 September 2020
- journal article
- review article
- Published by SAGE Publications in Cephalalgia
- Vol. 41 (2) , 247-255
Abstract
To evaluate the association between the degree of response to placebo in migraine studies and the observed difference between drug and placebo across studies of preventative treatments for migraine. A systematic review was performed using MEDLINE and the Cochrane Central Register of Controlled Clinical Trials from January 1988 to June 2019. Randomized, double-blind, parallel-group, placebo-controlled trials on oral or injection preventative treatments for migraine were included. Single- and multi-variable linear regression analyses were performed on the placebo-subtracted response rate (i.e. placebo responders subtracted from active responders), and the proportion of placebo responders. Fisher’s exact tests were performed on the level of placebo response and the success in meeting the study’s primary endpoint. After adjusting for route of administration and number of randomized subjects, there was a statistically significant association between the proportion of patients who were placebo responders and the placebo-subtracted response rate (b = −0.27, p = 0.02). There was a statistically significant difference in trial success rate (60%) between studies with ≤20% placebo responders and studies with > 30% placebo responders (p = 0.03). Considering the detrimental impact that high placebo response can have on clinical trials, it is imperative to find effective solutions to decrease the placebo response and increase assay sensitivity.Keywords
This publication has 43 references indexed in Scilit:
- Publication bias: What are the challenges and can they be overcome?Journal of Psychiatry and Neuroscience, 2012
- The Cochrane Collaboration's tool for assessing risk of bias in randomised trialsBMJ, 2011
- Evidence-based clinical trial design for chronic pain pharmacotherapy: A blueprint for ACTIONPain, 2011
- Lack of efficacy of the selective iNOS inhibitor GW274150 in prophylaxis of migraine headacheCephalalgia, 2010
- Telmisartan in Migraine Prophylaxis: A Randomized, Placebo-Controlled TrialCephalalgia, 2009
- Randomized trial of the effect of drug presentation on asthma outcomes: The American Lung Association Asthma Clinical Research CentersJournal of Allergy and Clinical Immunology, 2009
- Initial Severity and Antidepressant Benefits: A Meta-Analysis of Data Submitted to the Food and Drug AdministrationPLOS Medicine, 2008
- Botulinum Toxin A in the Prophylactic Treatment of Migraine – A Randomized, Double-Blind, Placebo-Controlled StudyCephalalgia, 2004
- Montelukast for Migraine Prophylaxis: A Randomized, Double‐Blind, Placebo‐Controlled StudyHeadache: The Journal of Head and Face Pain, 2004
- Cyclandelate in the Prophylaxis of MigraineCephalalgia, 1996